Search
for
Sort by
Research 181–210 of 189
- A systematic review on Drug Re-profiling/Re-Purposing
- CAQ Corner: Basic concepts of transplant immunology
- 467 Novel selective phosphodiesterase inhibitors promote the adipogenic function of dermal fibroblasts: Implication to treat hair loss
- Subject Index
- Subject Index
- ZALCITABINE
- TACRINE
- SARGRAMOSTIN
- ETHANOLAMINE
- Hair graying and loss induced by imatinib mesylate
- Imatinib-induced classical lichen planopilaris in blaschko-linear distribution leading to cicatricial alopecia
- Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- The PDGF/PDGFR pathway as a drug target
- Cutaneous Scarring: Basic Science, Current Treatments, and Future Directions
- Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas
- Tyrosine kinase inhibition and grey hair
- Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia
- Skin toxicity of anti‐cancer therapy
- Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
- Author reply
- Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique
- Skin manifestations of chronic kidney disease
- Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
- Nilotinib-Induced Keratosis Pilaris
- The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
- Targeted therapy in melanoma
- Updates from the British Association of Dermatologists 91st Annual Meeting, 5-7 July 2011, London, U.K.
- Solitary, subcutaneous, fixed, firm, and fast-growing nodule
- Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical <i>in silico/in vitro</i> screening methods